Brokerages expect Regenxbio Inc (NASDAQ:RGNX) to announce sales of $10.00 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Regenxbio’s earnings. Regenxbio posted sales of $2.04 million in the same quarter last year, which would indicate a positive year over year growth rate of 390.2%. The company is scheduled to issue its next quarterly earnings results on Tuesday, March 5th.
According to Zacks, analysts expect that Regenxbio will report full-year sales of $210.06 million for the current fiscal year, with estimates ranging from $187.73 million to $232.40 million. For the next financial year, analysts forecast that the business will report sales of $22.71 million, with estimates ranging from $13.70 million to $33.93 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Regenxbio.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. The business had revenue of $5.31 million for the quarter.
Several brokerages have recently weighed in on RGNX. ValuEngine downgraded Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. BidaskClub downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Barclays increased their price target on Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Raymond James set a $96.00 price target on Regenxbio and gave the stock a “buy” rating in a report on Thursday, November 8th. Finally, Bank of America increased their price target on Regenxbio from $76.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Regenxbio has a consensus rating of “Hold” and a consensus price target of $77.81.
Shares of NASDAQ RGNX opened at $52.44 on Friday. Regenxbio has a fifty-two week low of $23.25 and a fifty-two week high of $85.10. The company has a market capitalization of $1.96 billion, a PE ratio of -21.40, a price-to-earnings-growth ratio of 8.05 and a beta of -0.53.
In other Regenxbio news, SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction on Thursday, October 18th. The stock was sold at an average price of $61.78, for a total transaction of $308,900.00. Following the transaction, the senior vice president now directly owns 22,669 shares in the company, valued at approximately $1,400,490.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Curran Simpson sold 62,309 shares of the firm’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $60.85, for a total value of $3,791,502.65. Following the transaction, the senior vice president now owns 86,017 shares in the company, valued at $5,234,134.45. The disclosure for this sale can be found here. Over the last quarter, insiders sold 448,954 shares of company stock worth $28,902,916. Company insiders own 16.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in Regenxbio by 12.1% during the 3rd quarter. BlackRock Inc. now owns 4,727,045 shares of the biotechnology company’s stock worth $356,893,000 after purchasing an additional 508,632 shares during the period. Vanguard Group Inc. increased its holdings in Regenxbio by 51.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock worth $211,851,000 after purchasing an additional 947,671 shares during the period. RTW Investments LP increased its holdings in Regenxbio by 10.7% during the 2nd quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after purchasing an additional 201,788 shares during the period. Redmile Group LLC increased its holdings in Regenxbio by 6.1% during the 3rd quarter. Redmile Group LLC now owns 1,656,065 shares of the biotechnology company’s stock worth $125,033,000 after purchasing an additional 94,890 shares during the period. Finally, Credit Suisse AG increased its holdings in Regenxbio by 31.4% during the 3rd quarter. Credit Suisse AG now owns 444,911 shares of the biotechnology company’s stock worth $33,591,000 after purchasing an additional 106,333 shares during the period. Institutional investors own 79.08% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
See Also: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.